NASDAQ:PRLD - Nasdaq - US74065P1012 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to PRLD. PRLD was compared to 551 industry peers in the Biotechnology industry. The financial health of PRLD is average, but there are quite some concerns on its profitability. PRLD is valued expensive and it does not seem to be growing.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -72.46% | ||
ROE | -96.74% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.83 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.3 | ||
Quick Ratio | 5.3 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
0.857
+0.01 (+0.85%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 6.91 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.37 | ||
P/tB | 0.37 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -72.46% | ||
ROE | -96.74% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 43.12% | ||
Cap/Sales | 10.91% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.3 | ||
Quick Ratio | 5.3 | ||
Altman-Z | -5.83 |